| Year |
Citation |
Score |
| 2024 |
Chen M, Yin B, Liu Y, Li M, Shen S, Wu J, Li W, Fan J. ARRDC3 regulates the targeted therapy sensitivity of clear cell renal cell carcinoma by promoting AXL degradation. Cell Cycle (Georgetown, Tex.). 1-14. PMID 38389126 DOI: 10.1080/15384101.2024.2308411 |
0.331 |
|
| 2023 |
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, et al. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. The Lancet. Oncology. PMID 38092009 DOI: 10.1016/S1470-2045(23)00589-2 |
0.33 |
|
| 2023 |
Arwood ML, Liu Y, Harkins SK, Weinstock DM, Yang L, Stevenson KE, Plana OD, Dong J, Cirka H, Jones KL, Virtanen AT, Gupta DG, Ceas A, Lawney B, Yoda A, et al. New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. Cell Chemical Biology. PMID 37290440 DOI: 10.1016/j.chembiol.2023.05.007 |
0.517 |
|
| 2023 |
Wang K, Lu H, Wang X, Liu Q, Hu J, Liu Y, Jin M, Kong D. Simultaneous suppression of PKM2 and PHGDH elicits synergistic anti-cancer effect in NSCLC. Frontiers in Pharmacology. 14: 1200538. PMID 37284309 DOI: 10.3389/fphar.2023.1200538 |
0.306 |
|
| 2023 |
Lu W, Liu Y, Gao Y, Geng Q, Gurbani D, Li L, Ficarro SB, Meyer CJ, Sinha D, You I, Tse J, He Z, Ji W, Che J, Kim AY, et al. Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1. Journal of Medicinal Chemistry. 66: 3356-3371. PMID 36826833 DOI: 10.1021/acs.jmedchem.2c01834 |
0.72 |
|
| 2022 |
Fan M, Lu W, Che J, Kwiatkowski NP, Gao Y, Seo HS, Ficarro SB, Gokhale PC, Liu Y, Geffken EA, Lakhani J, Song K, Kuljanin M, Ji W, Jiang J, et al. Covalent disruptor of YAP-TEAD association suppresses defective hippo signaling. Elife. 11. PMID 36300789 DOI: 10.7554/eLife.78810 |
0.499 |
|
| 2021 |
Zhang S, Peng X, Li X, Liu H, Zhao B, Elkabets M, Liu Y, Wang W, Wang R, Zhong Y, Kong D. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. Cell Death & Disease. 12: 546. PMID 34039959 DOI: 10.1038/s41419-021-03805-6 |
0.304 |
|
| 2021 |
Jiang T, Wang G, Liu Y, Feng L, Wang M, Liu J, Chen Y, Ouyang L. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for fusion cancers. Acta Pharmaceutica Sinica. B. 11: 355-372. PMID 33643817 DOI: 10.1016/j.apsb.2020.05.004 |
0.373 |
|
| 2020 |
Liu Y, Hao M, Leggett A, Gao Y, Ficarro SB, Che J, He Z, Olson C, Marto JA, Kwiatkowski N, Zhang T, Gray NS. Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13. Journal of Medicinal Chemistry. PMID 32502343 DOI: 10.1021/Acs.Jmedchem.9B01929 |
0.762 |
|
| 2020 |
Wang G, Zhao Y, Liu Y, Sun D, Zhen Y, Liu J, Fu L, Zhang L, Ouyang L. Discovery of a novel dual-target inhibitor of ERK1 and ERK5 that induces regulated cell death to overcome compensatory mechanism in specific tumor types. Journal of Medicinal Chemistry. PMID 32078308 DOI: 10.1021/acs.jmedchem.9b01896 |
0.305 |
|
| 2020 |
Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, Portell A, Lizotte PH, Ficarro SB, Li S, Chen T, et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 37: 104-122.e12. PMID 31935369 DOI: 10.1016/J.Ccell.2019.12.006 |
0.568 |
|
| 2019 |
Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, Edlinger L, Knab VM, Uras IZ, Grundschober E, Bauer K, Roth M, Skucha A, Liu Y, Hatcher JM, et al. A kinase-independent role for CDK8 in BCR-ABL1 leukemia. Nature Communications. 10: 4741. PMID 31628323 DOI: 10.1038/S41467-019-12656-X |
0.771 |
|
| 2018 |
Czarna A, Wang J, Zelencova D, Liu Y, Deng X, Choi HG, Zhang T, Zhou W, Chang JW, Kildalsen H, Seternes OM, Gray NS, Engh RA, Rothweiler U. Novel scaffolds for Dual specificity tyrosine-phosphorylation-regulated kinase (DYRK1A) inhibitors. Journal of Medicinal Chemistry. PMID 30095246 DOI: 10.1021/acs.jmedchem.7b01847 |
0.694 |
|
| 2017 |
Chen S, Guan X, Wang LL, Li B, Sang XB, Liu Y, Zhao Y. Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4. Gene. PMID 28888575 DOI: 10.1016/j.gene.2017.09.009 |
0.355 |
|
| 2017 |
Weir MC, Hellwig S, Tan L, Liu Y, Gray NS, Smithgall TE. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. Plos One. 12: e0181178. PMID 28727840 DOI: 10.1371/Journal.Pone.0181178 |
0.584 |
|
| 2016 |
Zhao GZ, Zhang LQ, Liu Y, Fang J, Li HZ, Gao KH, Chen YZ. Effects of platelet-derived growth factor on chondrocyte proliferation, migration and apoptosis via regulation of GIT1 expression. Molecular Medicine Reports. PMID 27220359 DOI: 10.3892/mmr.2016.5291 |
0.326 |
|
| 2016 |
Udayakumar D, Pandita RK, Horikoshi N, Liu Y, Liu Q, Wong KK, Hunt CR, Gray NS, Minna JD, Pandita TK, Westover KD. Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. Radiation Research. PMID 27135971 DOI: 10.1667/Rr14373.1 |
0.686 |
|
| 2016 |
Liu J, Zhang Y, Liu A, Wang J, Li L, Chen X, Gao X, Xue Y, Zhang X, Liu Y. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells. International Journal of Molecular Sciences. 17. PMID 27070592 DOI: 10.3390/ijms17040531 |
0.304 |
|
| 2015 |
Ran Q, Xiang Y, Liu Y, Xiang L, Li F, Deng X, Xiao Y, Chen L, Chen L, Li Z. Eryptosis Indices as a Novel Predictive Parameter for Biocompatibility of Fe3O4 Magnetic Nanoparticles on Erythrocytes. Scientific Reports. 5: 16209. PMID 26537855 DOI: 10.1038/srep16209 |
0.409 |
|
| 2015 |
Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, et al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. PMID 26165234 DOI: 10.1038/Leu.2015.180 |
0.674 |
|
| 2015 |
Huang Z, Tan L, Wang H, Liu Y, Blais S, Deng J, Neubert TA, Gray NS, Li X, Mohammadi M. DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors. Acs Chemical Biology. 10: 299-309. PMID 25317566 DOI: 10.1021/Cb500674S |
0.524 |
|
| 2014 |
Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, ... Liu Y, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 26: 909-22. PMID 25490451 DOI: 10.1016/J.Ccell.2014.10.019 |
0.481 |
|
| 2014 |
Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? Acs Chemical Biology. 9: 1230-41. PMID 24730530 DOI: 10.1021/Cb500129T |
0.628 |
|
| 2013 |
Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discovery. 3: 870-9. PMID 23715154 DOI: 10.1158/2159-8290.Cd-13-0015 |
0.579 |
|
| 2013 |
Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Research. 73: 2574-86. PMID 23436801 DOI: 10.1158/0008-5472.Can-12-1702 |
0.738 |
|
| 2010 |
Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, et al. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. Journal of Medicinal Chemistry. 53: 5439-48. PMID 20604564 DOI: 10.1021/Jm901808W |
0.55 |
|
| 2010 |
Zhang J, Adrián FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, Guo GR, Ding Q, Okram B, Choi Y, Wojciechowski A, ... ... Liu Y, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 463: 501-6. PMID 20072125 DOI: 10.1038/Nature08675 |
0.616 |
|
| 2009 |
Zhang G, Ren P, Gray NS, Sim T, Wang X, Liu Y, Che J, Dong W, Tian SS, Sandberg ML, Spalding TA, Romeo R, Iskandar M, Wang Z, Seidel HM, et al. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II. Bioorganic & Medicinal Chemistry Letters. 19: 6691-5. PMID 19854052 DOI: 10.1016/J.Bmcl.2009.09.123 |
0.575 |
|
| 2008 |
Zhang G, Ren P, Gray NS, Sim T, Liu Y, Wang X, Che J, Tian SS, Sandberg ML, Spalding TA, Romeo R, Iskandar M, Chow D, Martin Seidel H, Karanewsky DS, et al. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I. Bioorganic & Medicinal Chemistry Letters. 18: 5618-21. PMID 18793846 DOI: 10.1016/J.Bmcl.2008.08.104 |
0.571 |
|
| 2008 |
Andersen CB, Wan Y, Chang JW, Riggs B, Lee C, Liu Y, Sessa F, Villa F, Kwiatkowski N, Suzuki M, Nallan L, Heald R, Musacchio A, Gray NS. Discovery of selective aminothiazole aurora kinase inhibitors. Acs Chemical Biology. 3: 180-92. PMID 18307303 DOI: 10.1021/Cb700200W |
0.579 |
|
| 2007 |
Jansma A, Zhang Q, Li B, Ding Q, Uno T, Bursulaya B, Liu Y, Furet P, Gray NS, Geierstanger BH. Verification of a designed intramolecular hydrogen bond in a drug scaffold by nuclear magnetic resonance spectroscopy Journal of Medicinal Chemistry. 50: 5875-5877. PMID 17975906 DOI: 10.1021/jm700983a |
0.351 |
|
| 2007 |
Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding P, Liu Y, Sun F, Schultz PG, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences of the United States of America. 104: 270-5. PMID 17185414 DOI: 10.1073/Pnas.0609412103 |
0.638 |
|
| 2006 |
Pan S, Mi Y, Pally C, Beerli C, Chen A, Guerini D, Hinterding K, Nuesslein-Hildesheim B, Tuntland T, Lefebvre S, Liu Y, Gao W, Chu A, Brinkmann V, Bruns C, et al. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chemistry & Biology. 13: 1227-34. PMID 17114004 DOI: 10.1016/J.Chembiol.2006.09.017 |
0.382 |
|
| 2006 |
Okram B, Nagle A, Adrián FJ, Lee C, Ren P, Wang X, Sim T, Xie Y, Wang X, Xia G, Spraggon G, Warmuth M, Liu Y, Gray NS. A general strategy for creating "inactive-conformation" abl inhibitors. Chemistry & Biology. 13: 779-86. PMID 16873026 DOI: 10.1016/J.Chembiol.2006.05.015 |
0.514 |
|
| 2006 |
Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nature Chemical Biology. 2: 358-64. PMID 16783341 DOI: 10.1038/nchembio799 |
0.566 |
|
| 2006 |
Choi HS, Wang Z, Richmond W, He X, Yang K, Jiang T, Karanewsky D, Gu XJ, Zhou V, Liu Y, Che J, Lee CC, Caldwell J, Kanazawa T, Umemura I, et al. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2. Bioorganic & Medicinal Chemistry Letters. 16: 2689-92. PMID 16524731 DOI: 10.1016/j.bmcl.2006.02.032 |
0.521 |
|
| 2006 |
Zhang Q, Liu Y, Gao F, Ding Q, Cho C, Hur W, Jin Y, Uno T, Joazeiro CA, Gray N. Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. Journal of the American Chemical Society. 128: 2182-3. PMID 16478150 DOI: 10.1021/Ja0567485 |
0.56 |
|
| 2006 |
Choi HS, Wang Z, Richmond W, He X, Yang K, Jiang T, Sim T, Karanewsky D, Gu XJ, Zhou V, Liu Y, Ohmori O, Caldwell J, Gray N, He Y. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1. Bioorganic & Medicinal Chemistry Letters. 16: 2173-6. PMID 16458503 DOI: 10.1016/J.Bmcl.2006.01.053 |
0.522 |
|
| 2006 |
Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P, Mestan J, Fabbro D, Gray NS. Allosteric inhibitors of Bcr-abl-dependent cell proliferation Nature Chemical Biology. 2: 95-102. PMID 16415863 DOI: 10.1038/Nchembio760 |
0.593 |
|
| 2005 |
Han S, Zhou V, Pan S, Liu Y, Hornsby M, McMullan D, Klock HE, Haugen J, Lesley SA, Gray N, Caldwell J, Gu XJ. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 15: 5467-73. PMID 16199156 DOI: 10.1016/J.Bmcl.2005.08.097 |
0.546 |
|
| 2004 |
Li B, Liu Y, Uno T, Gray N. Creating chemical diversity to target protein kinases. Combinatorial Chemistry & High Throughput Screening. 7: 453-72. PMID 15320712 DOI: 10.2174/1386207043328580 |
0.538 |
|
| 2004 |
Wan Y, Hur W, Cho CY, Liu Y, Adrian FJ, Lozach O, Bach S, Mayer T, Fabbro D, Meijer L, Gray NS. Synthesis and target identification of hymenialdisine analogs. Chemistry & Biology. 11: 247-59. PMID 15123286 DOI: 10.1016/j.chembiol.2004.01.015 |
0.549 |
|
| 2003 |
Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Current Pharmaceutical Design. 9: 2043-59. PMID 14529415 DOI: 10.2174/1381612033454126 |
0.557 |
|
| Show low-probability matches. |